Dive Brief:
- China’s five-year plan to strengthen its biotechnology industry and invent 25% of the world’s new drugs could allow the country to “corner the sector” and “leave American patients vulnerable to supply chain weaponization,” according to a report published Wednesday by a congressional commission.
- The report from the National Security Commission on Emerging Biotechnology endorsed a recent Treasury Department proposal to add biotech to the “COINS Act,” which could limit certain transactions with Chinese companies. But the commission also urged the government to “act now to empower the United States to out-innovate strategic competitors before it’s too late.”
- The commission’s report comes shortly after the Biotechnology Innovation Organization, a top industry lobbying group, unveiled a multifaceted plan to accelerate U.S. drug development and better compete with China going forward. More than 120 licensing deals between U.S. or European companies and Chinese drug developers have been struck since the start of 2025, according to BioPharma Dive data, reflecting the country’s fast biotech progress.
Dive Insight:
Even before the release of its latest biotech plan, China’s rise as a global pharmaceutical powerhouse had already rung alarm bells in Congress as well as the corporate suites of top drugmakers. Its new goal of ensuring the country produces a quarter of the world’s “first-in-class drugs” by 2030 has intensified concerns that the U.S. might soon lose a long-held edge and become overly dependent on China for new medicines.
The commission, an 11-member group that includes members of Congress, was formed by defense appropriations legislation in 2022 to study the state of biotechnology competition between the U.S. and other countries, particularly China. Its goal is to promote legislation to support the biotech industry, much as work by an earlier commission helped pave the way for the 2022 CHIPS Act aimed at semiconductor manufacturing and research.
The latest publication focuses on the kind of cross-border licensing deals that have become commonplace over the last few years. A large proportion of these transactions are based on preclinical research and are rising in value, signaling “a growing trust in China’s ability to innovate in the pharmaceutical sector.” The commission also pointed to “escalating deal structures” and repeat collaborations, which could transfer to China-based partners key knowledge such as “development, commercialization, and regulatory best practices for U.S. markets.”
“This type of knowledge transfer is well documented in the context of U.S. joint ventures into Chinese markets in the automobile, semiconductor, and industrial chemical sectors. In these cases, the Chinese industry gained a competitive edge and leveraged that edge to control the global market,” the report states.
“U.S.-China pharma deals are starting to favor the Chinese startups, which risks eroding biotech R&D in the U.S.,” said commission Chair Caitlin Frazer in a statement. “This trend should be alarming for policymakers.”
China’s embassy in the U.S. didn’t respond to a request for comment.